Compositions and methods using unbound mpl receptor for stimulating platelet production

A technology of platelets and compositions, applied in drug combinations, biochemical equipment and methods, receptors of cytokines/lymphokines/interferons, etc., can solve problems such as increased medical expenses and expensive platelets

Inactive Publication Date: 2001-09-19
AMGEN INC
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the production of purified platelets is expensive, so the use of platelets will increase the overall medical costs, so there is an urgent need for a new and improved method to produce platelets for human use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods using unbound mpl receptor for stimulating platelet production
  • Compositions and methods using unbound mpl receptor for stimulating platelet production
  • Compositions and methods using unbound mpl receptor for stimulating platelet production

Examples

Experimental program
Comparison scheme
Effect test

example

[0087] The following examples will illustrate the present invention in more detail. In addition, these Examples provide preferred specific examples of the present invention. It is not intended to limit the scope of the invention unless otherwise indicated. Standard methods for many of the experiments described in the following examples, or appropriate alternative procedures, are mentioned in well-known molecular biology handbooks, such as Sambrook et al., "Molecular Cloning," Second Edition, Cold Spring Harbor Laboratory Press ( 1987) and Ausubel et al., (Eds), "Current Protocols in Molecular Biology," Greeneassociates / Wiley Interscience, New York (1990).

example 1

[0089] Isolation of Nucleic Acid Sequences Encoding MPL Receptor

[0090] Encodes murine (Vigon et al., Oncogene 8:2607-2615 (1993)) and (Skoda et al., EMBO) 12(7):2645-2653 (1993)) and human (Vigon et al., DNAS89:5640 -5644 (1992)) isolation of a clone of the MPL receptor isotype has been published. These DNA sequences can be obtained from the GenBank database. The codes of the murine receptors are X73677 and 222657, and the codes of the human receptors K and P are M90102 and M90103, respectively. It has been reported that the mRNA of MPL can be expressed in spleen, bone marrow, placenta and fetal liver and other tissues. Tissue strains expressing MPL include HEL. Thus, it is clear to those skilled in the art how to isolate the gene encoding MPL. The cDNA can be produced from the above-mentioned tissue sources or cell lines or from other sources, and the expression of MPL in these sources can be confirmed by RNA Northern blot analysis or Western blot analysis.

[0091] Th...

example 2

[0094] Isolation of clones expressing soluble murine MPL

[0095] Using the above-mentioned clones confirmed to contain MPL, or cDNA obtained from a source capable of expressing MPL, a clone capable of expressing soluble MPL was obtained by PCR. The primers used for murine MPL PCR amplification may be in the following form: 5' end primer: TAC AAG CTT GCC GTC ATC ATG CCC TCT TGGGCC CTC (SEQ ID NO. 5); and 3' end primer: ACT TCT AGA CTA TCA AGC AGT CTC GGA GCTGGA (serial number 6)

[0096] The PCR reaction includes the following components: 1 microliter of cDNA reaction mixture, the above-mentioned various oligonucleotides containing Tris-HCl (pH8.3) at a concentration of 5 picomolar and 10 millimolar, and potassium chloride at a concentration of 50 millimolar. , magnesium chloride at a concentration of 1.5 millimolar, and each dNTP at a concentration of 200 micromolar and 1 unit of Taq polymerase, respectively. DNA amplification was set at 94°C for 30 seconds, at 50°C for 30 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed is a method for increasing the number of platelets in a mammal, which comprises administering to the mammal a platelet number increasing effective amount of an unbound, preferably a soluble, MPL receptor.

Description

field of invention [0001] The present invention relates to the stimulation and growth of cells, in particular megakaryocytes and platelets, and especially to the use of the so-called MPL receptor as an inducer of the differentiation of megakaryocytes into platelets. The invention also relates to compositions capable of inducing the production of platelets in vivo. Background of the invention [0002] The present invention encompasses at least two broad areas of research, the first relating to the development and production of platelets from megakaryocytes and the second relating to polypeptide members of the growth factor receptor family referred to herein as MPL receptors. Individual studies in these areas are outlined below. A. Platelets are produced by megakaryocytes [0003] Platelets are circulating cells that are important in impeding blood flow and facilitating blood clotting. Megakaryocytes are the cellular source of platelets, which arise from the common myeloid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/00A61K38/17A61P7/06A61P35/00C07K14/71C07K14/715C12N15/18
CPCC07K14/715A61K38/00A61P35/00A61P7/00A61P7/06
Inventor E·S·蔡M·M·霍科姆P·亨特J·L·尼科尔
Owner AMGEN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products